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Abstract
L-acetylcarnitine (LAC), a drug utilized for the treatment of neuropathic pain in humans, has been shown
to induce analgesia in rodents by up-regulating the expression of metabotropic glutamate receptor 2
(mGlu2) in dorsal root ganglia (DRG). We now report that LAC-induced upregulation of mGlu2
expression in DRG cultures involves transcriptional activation mediated by nuclear factor-kappaB (NF-κB).
A single application of LAC (250 μM) to DRG cultures induced a transient increase in mGlu2 mRNA,
which was observable after 1 hour and was no longer detectable after 1 to 4 days. In contrast, LAC
treatment had no effect on mGlu3 mRNA expression. Pharmacological inhibition of NF-κB binding to
DNA by caffeic acid phenethyl ester (CAPE) (2.5 μg/ml for 30 minutes) reduced the constitutive
expression of mGlu2 and mGlu3 mRNA after 1–4 days and reduced the constitutive expression of mGlu2/
3 protein at 4 days. This evidence combined with the expression of p65/RelA and c-Rel in DRG neurons
indicated that expression of mGlu2 and mGlu3 is endogenously regulated by the NF-κB family of
transcription factors. Consistent with this idea, the transient increase in mGlu2 mRNA induced by LAC
after 1 hour was completely suppressed by CAPE. Furthermore, LAC induced an increase in the
acetylation of p65/RelA, a process that enhances the transcriptional activity of p65/RelA. These results are
consistent with the hypothesis that LAC selectively induces the expression of mGlu2 by acting as a donor
of acetyl groups, thus enhancing the activity of the NF-κB family of transcription factors. Accordingly, we
show that carnitine, which has no effect on pain thresholds, had no effect on p65/RelA acetylation and did
not enhance mGlu2 expression. Taken together, these results demonstrate that expression of mGlu2 and
mGlu3 mRNA is regulated by the NF-κB transcriptional machinery, and that agents that increase
acetylation and activation of NF-κB transcription factors might induce analgesia via upregulation of mGlu2
in DRG neurons.
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Background
Activation of group II metabotropic glutamate receptors
(mGlu2 and mGlu3) induces antinociception in several
pain models in rodents [1-5]. Consistent with these stud-
ies, we have shown that L-acetylcarnitine (LAC), a drug
clinically effective in the treatment of neuropathic pain of
various origins [6-9], up-regulates the expression of
mGlu2 in the dorsal root ganglia (DRG) and in the dorsal
horn (DH) of the spinal cord [10,11]. This has challenged
the previous view that LAC increases pain thresholds and
relieves neuropathic pain by enhancing brain acetylcho-
line synthesis [12] or by increasing the trophism of
peripheral nerves [13,14]. Consistent with the "mGlu2
hypothesis of LAC-induced analgesia," the mGlu2/3
receptor antagonist, LY341495, prevents LAC-induced
analgesia in rodents [10]. Interestingly, LAC selectively
enhances the expression of mGlu2 receptors and has no
effect on the expression of mGlu3 receptors [10,15],
although these two receptor subtypes are highly homolo-
gous and share similar functions in the CNS [16]. This
suggests that the expression of mGlu2 and mGlu3 is dif-
ferentially regulated and that unraveling the nature of this
difference may lead to the identification of new targets for
the treatment of neuropathic pain.
Analysis of the 5'-region upstream of the coding sequence
of the human GRM2 gene (encoding mGlu2) [GenBank:
AB045011], using the Transcription Factor Binding Sites
Database TRANSFACT and TFSEARCH, revealed the pres-
ence of many potential regulatory elements for transcrip-
tion factors of the NF-κB family, including p50 and p65/
Rel-A, and for the coactivator p300. In contrast, only one
binding site for the NF-κB family protein, c-Rel, and no
binding sites for p65/RelA and p300 have been described
in the putative promoter region of the human GRM3 gene
encoding mGlu3 [17]. Hence, we focused on the NF-κB
pathway in the search for mechanisms that account for the
selective effect of LAC on mGlu2 expression.
NF-κB consists of transcription factor dimers, including
NF-κB p50, NF-κB p65/Rel-A, Rel-B, and c-Rel. The most
common combination is a heterodimer formed by the
p50 and p65/Rel-A subunits. Under basal conditions, NF-
κB is retained in the cytoplasm where it is bound and inac-
tivated by the endogenous inhibitor, IκBα [18]. Phospho-
rylation of IκBα through IκB kinases (IKK) leads to the
degradation of the inhibitory protein and activation of
NF-κB, which translocates into the nucleus and regulates
gene expression [19]. Interestingly, the transcriptional
activity of p65/Rel-A is regulated by acetylation, and p300
itself is endowed with acetyltransferase activity [20-23].
Given that in addition to its role in fatty acid metabolism
LAC also behaves as a donor of acetyl groups for amino
acids and proteins [24], we examined whether LAC-
induced mGlu2 upregulation is mediated by the NF-κB
pathway and depends on acetylation of transcription fac-
tors of the NF-κB family.
Results
Induction of the mGlu2 gene by LAC in cultured DRG 
neurons
LAC up-regulates the expression of mGlu2/3 protein in
cultured DRG neurons [15]. To examine the nature of this
effect, we measured the transcripts of mGlu2 and mGlu3
by real-time PCR. Cultures were exposed to LAC (250 μM,
applied every 12 hours) for various time periods from 30
min to 4 days. mGlu2 mRNA levels substantially
increased after 60 minutes and returned to control levels
after 120 min (Fig. 1A). In contrast, mGlu3 mRNA levels
did not change in response to LAC (Fig. 1B). These results
Time course analysis of mGlu2 and mGlu3 mRNA expression  after L-acetylcarnitine treatment Figure 1
Time course analysis of mGlu2 and mGlu3 mRNA 
expression after L-acetylcarnitine treatment. For 
short term treatments (30, 60, 120, and 240 minutes) DRG 
cultures were challenged with a single application of L-acetyl-
carnitine (250 μM). For long term treatments (1 day and 4 
days) L-acetylcarnitine (250 μM) was applied every 12 hrs to 
DRG cultures and total RNA was extracted at different time 
points. mRNA levels were normalized to the housekeeping 
gene, GAPDH, and compared to vehicle controls. Real-time 
PCR analysis shows that mGlu2 mRNA is upregulated after 
60 minutes following LAC treatment. Data are expressed as 
mean values ± SEM *p < 0.05Molecular Pain 2006, 2:20 http://www.molecularpain.com/content/2/1/20
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confirm our in vivo studies in which we showed that LAC
selectively induces mGlu2 mRNA expression in the rat
dorsal horn of the spinal cord and in the DRG without
affecting mGlu3 levels [10]. Addition of carnitine, the
non-acetylated analog of LAC, (250 μM) to the cultures
had no effect on the transcript of mGlu2 or mGlu3 at any
time points (not shown).
Expression of p65/Rel-A and c-Rel in DRG cultures
Previous reports have demonstrated the expression of
members of the NF-κB family of transcription factors in
the rat or mouse DRG [25-27]. We examined the expres-
sion of p65/Rel-A and c-Rel proteins by immunocyto-
chemistry, and found that both proteins were expressed
by cultured mouse DRG neurons. A faint immunoreactiv-
ity was also observed in glial cells identified by their typi-
cal morphology (Fig. 2A–C).
NF-κB regulates the constitutive expression of mGlu2 and 
mGlu3 in DRG cultures
We used the NF-κB inhibitor, caffeic acid phenethyl ester
(CAPE), to examine whether NF-κB regulates the constitu-
tive expression of mGlu2 and mGlu3 in DRG cultures.
CAPE acts as a specific inhibitor of NF-κB binding to DNA
[28]. We first examined the effect of CAPE on the expres-
sion of mGlu2 and mGlu3 mRNAs at different time
points. Cultures were incubated with CAPE (2.5 μg/ml) or
vehicle for 30 min, and mGlu2 and mGlu3 mRNA levels
were assessed after 1 hour, 1 day or 4 days. CAPE did not
affect mGlu2 or mGlu3 mRNA levels after 1 hour, but sub-
stantially reduced both transcripts after 1 or 4 days (Fig.
3A–B). We then examined the effect of CAPE on the
expression of mGlu2/3 protein at 4 days. We first ana-
lyzed mGlu2/3 expression by immunocytochemistry
(using an antibody that recognizes both mGlu2 and
mGlu3) in DRG cultures treated with vehicle or CAPE.
The expression of mGlu2/3 was clearly down-regulated
after 4 days of CAPE treatment compared to vehicle (Fig.
4A–B). In order to quantify the changes in mGlu2/3
expression, we performed in-cell  Western analysis, and
found that addition of CAPE significantly reduced the
expression of mGlu2/3 protein relative to vehicle-treated
cultures (Fig. 4C). These data suggest that endogenous
NF-κB activation regulates the constitutive expression of
mGlu2 and mGlu3.
Inhibition of NF-κB suppresses the transient increase in 
mGlu2 mRNA induced by LAC in DRG cultures
We next examined whether the NF-κB pathway mediates
the induction of mGlu2 mRNA by LAC in DRG cultures.
DRG cultures were pretreated with CAPE (2.5 μg/ml) or
vehicle for 30 minutes before being challenged with LAC.
LAC failed to increase mGlu2 mRNA after 1 hour in cul-
tures pretreated with CAPE (Fig. 5). It is noteworthy that
CAPE applied alone has no effect on mGlu2 mRNA at this
time point (see above). Thus, activation of the NF-κB
pathway mediates the induction of mGlu2 expression by
LAC.
Expression of the NF-κB family members, p65/Rel-A and c- Rel, in DRG cultures from newborn (PN1/2) mice Figure 2
Expression of the NF-κB family members, p65/Rel-A 
and c-Rel, in DRG cultures from newborn (PN1/2) 
mice. Micrographs of p65/Rel-A-immunoreactive (IR) (A) 
and and c-Rel-IR (B) neurons in mixed DRG cultures. Most 
NF-κB-IR neurons were medium sized-cells. Some small and 
large DRG neurons were also NF-κB-IR. No signal is 
observed in the absence of primary antibodies (C).Molecular Pain 2006, 2:20 http://www.molecularpain.com/content/2/1/20
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LAC enhances p65/Rel-A acetylation in DRG cultures
Acetylation of p65/Rel-A is an important mechanism in
the regulation of gene expression by NF-κB [20,22]. Due
to evidence that LAC can behave as a donor of acetyl
groups [24], and that the mGlu2 gene has multiple
responsive elements to p65/RelA, we examined whether
LAC treatment affects the levels of acetylated p65/Rel-A in
DRG cultures. Cultures were treated with LAC (250 μM)
or vehicle, and after 1 hour, cells were lysed and p65/Rel-
A was immunoprecipitated with anti-p65 antibodies. Fol-
lowing separation via SDS-PAGE, proteins were probed
with anti-acetyl-lysine antibodies. LAC substantially
increased the level of acetylated p65/Rel-A (Fig. 6A). As
controls, parallel cultures were treated with carnitine (250
μM). This treatment did not affect acetylation of p65/Rel-
A (Fig. 6B), suggesting that LAC acts as an acetyl donor
and its effect is not mediated by the carnitine moiety.
Discussion
mGlu2 mRNA expression has been shown to be increased
by LAC both in the dorsal horn of the rat spinal cord and
in the DRG (Chiechio et al., 2002, and this study). Here
we demonstrate that NF-κB transcriptional activity influ-
ences the constitutive expression of mGlu2/3 in DRG cul-
tures and that LAC-induced up-regulation of mGlu2
expression is also dependent on NF-κB activity.
NF-κB activity is reciprocally regulated by RelA/p65
acetylation and deacetylation, which may be mediated by
p300 or CBP acetyltransferases and histone deacetylase 3
[20]. In its acetylated state, NF-κB is resistant to the inhib-
itory effect of I-κB and therefore its binding affinity to
DNA containing NF-κB binding sites is enhanced [20,22].
LAC, behaving as donor of acetyl groups, could induce
mGlu2 mRNA expression by promoting the acetylation of
p65/Rel-A. This hypothesis is supported by our results
showing that LAC treatment induces an increase in the
levels of acetylated p65/Rel-A in DRG cultures. The mech-
anism by which LAC increases p65/Rel-A acetylation lev-
els remains to be determined; however, the observation
that L-carnitine was unable to affect p65/Rel-A acetylation
in DRG cultures suggests that the acetyl moiety of the drug
is involved in this mechanism. In vivo studies demonstrat-
ing that the analgesic effect of LAC is not shared by the
non acetylated derivative L-carnitine [12] also corroborate
our hypothesis that the acetyl moiety is of fundamental
importance for promoting the transcriptional activity of
NF-κB and therefore the induction of mGlu2, which in
turn are responsible for the analgesic effect of LAC
[10,11].
Although the basal expression of both mGlu2 and mGlu3
mRNA was regulated by NF-κB, LAC induced mGlu2, but
not mGlu3, mRNA expression. This evidence suggested
that NF-κB-dependent mGlu3 transcription did not
involve p65/Rel-A elements. Hence, similar to their
human homologs, the promoter regions of mouse GRM2
and GRM3 genes might bind different NF-κB family mem-
bers. Consistent with this hypothesis, the NF-κB family
member c-Rel, which is not activated by acetylation, is
expressed in cultured DRG neurons (Fig 2B). Future stud-
ies should examine whether mGlu3 expression is regu-
lated by c-Rel or another NF-κB family member.
NF-κB plays a pivotal role in regulating pro-inflammatory
cytokine gene expression [19], and is thus involved in the
genesis and persistence of pain after nerve injury [27]. NF-
κB is also required for electroacupuncture-induced anal-
gesia [29], and it is involved in inflammation-induced
analgesia through the upregulation of μ-opioid receptors
[30]. Whether mGlu2/3 modulation by the NF-κB path-
way occurs under conditions of inflammatory pain still
has to be determined. Interestingly, changes in the expres-
sion of metabotropic glutamate receptors during inflam-
mation have been reported by several authors. In
particular, an increased expression of mGlu3 mRNA and
protein after peripheral inflammation has been demon-
Time course analysis of mGlu2 and mGlu3 mRNAexpression  after CAPE treatment Figure 3
Time course analysis of mGlu2 and mGlu3 mRNAex-
pression after CAPE treatment. mGlu2 (A) and mGlu3 
(B) mRNA were quantified and normalized to the house-
keeping gene, GAPDH. Data are expressed as percentage of 
controls (mean values ± SEM) *p < 0.05 vs control levels.Molecular Pain 2006, 2:20 http://www.molecularpain.com/content/2/1/20
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strated in the rat spinal cord [31,32]. Since NF-κB activa-
tion can be triggered by inflammatory mediators in
neurons [33,34], it is likely that the NF-κB pathway is
involved in the regulation of metabotropic glutamate
receptors observed in vivo.
We now suggest that NF-κB-mediated mGlu2 upregula-
tion might be responsible for the analgesic effects of LAC
against peripheral nerve injury and in acute thermal pain
[10]. Anticonvulsant and antidepressant drugs are com-
monly used to treat neuropathic pain syndromes [35,36].
Remarkably, many of these drugs are able to inhibit his-
tone deacetylase (HDAC) and therefore increase protein
acetylation. Among anticonvulsants used in chronic pain
therapy, carbamazepine, valproic acid and topiramate are
known to inhibit HDAC and increase protein acetylation
levels [37,38]. Whether increased acetylation leads to the
upregulation of group II metabotropic glutamate recep-
tors has to be determined. Interestingly, the tricyclic anti-
depressant, imipramine, which is also able to up-regulate
group II metabotropic glutamate receptors [39] has
recently been shown to increases histone acetylation by
down-regulating HDACs [40]. The present results com-
bined with the previous studies described above suggest
the possibility that acetylating agents might be beneficial
as analgesics in chronic pain conditions.
Conclusion
In the present study, we demonstrate that expression of
mGlu2 and mGlu3 mRNA is regulated by the NF-κB tran-
mGlu2/3 expression in DRG neuronal cultures following the inhibition of the NF-κB transcriptional activity Figure 4
mGlu2/3 expression in DRG neuronal cultures following the inhibition of the NF-κB transcriptional activity. (A-
B) Immunocytochemical analysis of mGlu2/3 in mouse DRG cultures treated with vehicle or CAPE (2.5 μg/ml for 30 min) 
respectively. (C) Upper Panel: In-Cell western image for mGluR2/3 (green fluorescence) and MAP-2 (red fluorescence) in 
mouse DRG cultures in the absence or presence of CAPE (2.5 μg/ml for 30 min). Lower panel: Quantification of mGlu2/3 
expression normalized to MAP-2 protein expression. Infrared fluorescence levels were measured 4 days after CAPE incuba-
tion. Results are expressed as the mean ± SEM of 6 different determinations. *p < 0.05, vs vehicle (Student's t test).Molecular Pain 2006, 2:20 http://www.molecularpain.com/content/2/1/20
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scriptional machinery. Furthermore, LAC upregulates
mGlu2, but not mGlu3, mRNA via activation of NF-κB,
and increases acetylation of p65/Rel-A. We postulate that
agents that increase acetylation and activation of NF-κB
transcription factors might induce analgesia via upregula-
tion of mGlu2 in DRG neurons.
Methods
Preparation of DRG neuronal cultures
All experiments were performed in DRG cultures. DRGs
from newborn ICR mice PN1-2 were placed in HBSS
(Gibco), and then digested with 0.05% collagenase and
0.25% trypsin (Sigma) for 25 min at 37°C. Ganglia were
washed three times in HBSS and then resuspended in
Neurobasal media (Gibco) containing 10% FBS (Life
Technologies), 100 U/ml penicillin/streptomycin (Invit-
rogen), and 2 mM Glutamax (Invitrogen). Ganglia were
then triturated through a flame-polished Pasteur pipette
~10 times. The suspension was filtered through a 70 μm
nylon cell strainer (Falcon) and plated on 35 mm dishes
coated with poly-D-lysine (Sigma). Cells were grown in a
humidified incubator at 37°C in 5% CO2.
Cell treatments
CAPE (Calbiochem) was dissolved in DMSO, stored at -
20°C and diluted in culture growth media to a final con-
centration of 2.5 μg/ml in 0.001% DMSO prior to treat-
ments. For control experiments, 0.001% DMSO in growth
media was used. For L-acetylcarnitine or L-carnitine
(Sigma) treatments, the drugs were dissolved in growth
media to a final concentration of 250 μM immediately
before the treatments. For these experiments, growth
media was used as vehicle control. In long term treat-
ments, L-acelylcarnitine was administered every 12 hrs.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) (pH 7.4), blocked with 3% normal
goat serum and incubated with primary antibodies in PBS
containing 0.01% Tween-20 and 3% normal goat serum
(Vector) at 4°C overnight. The primary antibodies used
were: rabbit polyclonal anti p65/Rel-A and anti c-Rel
(Santa Cruz Biotechnology). Cells were then incubated
with a biotinylated goat anti-rabbit immunoglobulin
(Vector) for 1 hr and then with extravidin (Sigma). Immu-
noreactivity was visualized using 3,3'-diaminobenzidine
(DAB) (Vector).
Real-Time PCR
Real-Time PCR for detecting mGlu2 and mGlu3 mRNA
was performed using the Mx 4000™ Multiplex Quantita-
tive PCR System (Stratagene, La Jolla, CA). Total RNA,
extracted using TRIzol Reagent™ (Invitrogen, Carlsbad,
CA), was converted into cDNA and was amplified by Real-
Time PCR in a "one-step" reaction (Qiagen, OneStep RT-
PCR, Germantown, MD, USA). Amplification primers for
mGlu2 and mGlu3 were: mGlu2 5'-GGCCATGGCTGA-
GATTCTCC-3', 3'-TGTTGCAGAAGCCCAGCGCC-5';
mGlu3 5'-TCCCAGTGCAGTGATCCCTG-3', 3'-AGT-
GGCCCACTGCAGACCTA-5'. SYBR Green was used as a
fluorogenic probe system. Mx 4000™ Multiplex Quantita-
tive PCR System software (Stratagene, La Jolla, CA) was
used to analyze PCR kinetics and for quantification of the
data using the standard curve method.
Serial ten-fold dilutions of target genes and GAPDH were
used to generate the standard curve. The calculated Ct val-
ues were plotted versus the log of the initial amount of the
genes to generate the standard curve. For each experimen-
tal sample, the copy numbers of mGlu2, mGlu3 and
GAPDH were extrapolated from the respective standard
curve. Then, the gene target copy numbers were divided by
the endogenous value to normalize for target gene mRNA
expression to avoid sample-to-sample differences in RNA
quantity. No template controls, duplicates of each stand-
ard sample and triplicates of each experimental sample
were used in each run.
Immunoprecipitation and Western blotting
After pharmacological treatments, DRG cultures were
incubated for 5 minutes with 0.5 ml of lysis buffer (50
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25 Na-
Inhibition of NF-κB prevents the up-regulation of mGlu2  mRNA induced by L-acetylcarnitine treatment Figure 5
Inhibition of NF-κB prevents the up-regulation of 
mGlu2 mRNA induced by L-acetylcarnitine treat-
ment. CAPE (2.5 μg/ml) was applied to DRG cultures 30 
minutes before L-acetylcarnitine (LAC) (250 μM). 1 hr after 
LAC treatment total RNA was extracted. mRNA levels were 
normalized to the housekeeping gene, GAPDH, and com-
pared to controls. Real-time PCR analysis shows that mGlu2 
mRNA upregulation induced by LAC is blocked by CAPE 
treatment. Data are expressed as mean values ± SEM *p < 
0.05 vs controls, #p < 0.05 vs LAC (ANOVA).Molecular Pain 2006, 2:20 http://www.molecularpain.com/content/2/1/20
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Deoxycholate, 1 mM EDTA) containing deacetylase inhib-
itors (10 mM Nicotinamide, and 1 μM TSA), protease
inhibitors (1 mM PMSF, 1 μg/ml aprotinin, and 1 μg/ml
leupeptin) and phosphatase inhibitors (1 mM NaF, and 1
mM Na3VO4). Cells were disrupted by aspiration through
a 21 gauge needle. Lysates from three dishes for each con-
dition were collected and centrifuged at 10,000 × g for 10
min at 4°C. Supernatants were collected and, after protein
quantification, diluted to 500 μg in 500 μl. The proteins
were then added with a polyclonal antibody anti-p65
(Santa Cruz) for 12 hr at 4°C. 20 μl of resuspended Pro-
tein A/G-Agarose beads (50% slurry) were added to the
tube and incubated for 3 hours at 4°C. The immunopre-
cipitate was collected by centrifugation at 1,000 × g for 5
minutes at 4°C and washed three times with lysis buffer.
The beads were then resuspended in 20 μl of 3X loading
buffer and boiled for 5 min. Immunoprecipitates were
separated by SDS-PAGE and transferred onto protein-sen-
sitive nitrocellulose membranes (Criterion blotter, Bio-
Rad). The membrane was blocked in Odyssey blocker (Li-
COR) for 1 hr and anti-acetyl-lysine (Upstate) and anti-
p65/Rel-A (Santa Cruz) primary antibody were simultane-
ously used for immunoblotting overnight at 4°C. The
membrane was then incubated with a goat anti-rabbit
antibody labeled with IRD800CW and a goat anti-mouse
antibody labeled with Alexa 680 (LI-COR) for 1 hr at
room temperature. Proteins were detected with the Odys-
sey Infrared Fluorescence Imaging System (LI-COR Inc.).
In-cell Western assay
In-cell Western assays were used to quantify mGlu2/3 and
MAP-2 levels in plated fixed DRG cultures. DRG dissoci-
ated cells were plated in 96 multiwell plates coated with
poly-D-lysine (Sigma). After 4% paraformaldehyde fixa-
Acetylation of p65/Rel-A induced by L-acetylcarnitine treatment Figure 6
Acetylation of p65/Rel-A induced by L-acetylcarnitine treatment. p65/Rel-A was immunoprecipitated from DRG cul-
tures after L-acetylcarnitine (A) or carnitine (B) treatment. Western blots show immunoreactivity for anti-acetyl-lysine (red 
fluorescence) and anti-p65 (green fluorescence). A single red band migrating at ~65 kDa was identified on Western blots. 
Western blots demonstrate that L-acetylcarnitine (A), but not carnitine (B) treatment induces acetylation of the p65/Rel-A 
protein. (C) Results are expressed as ratio of integrated intensity of acetyl-lysine and p65 bands. *p < 0.05 vs controls (Stu-
dent's t test).Molecular Pain 2006, 2:20 http://www.molecularpain.com/content/2/1/20
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tion, and blocking in Odyssey blocker (Li-COR, Bio-
science) for 1 hr at room temperature, cells were
simultaneously incubated with anti-mGluR2/3 (Chemi-
con) and anti-MAP-2 (Sigma) primary antibodies over-
night at 4°C. Cells were then incubated with a goat anti-
rabbit antibody labeled with IRD800CW and a goat anti-
mouse antibody labeled with Alexa 680 (LI-COR, Bio-
science) for 1 hr at room temperature. After washing, mul-
tiwell plates were scanned using an Odyssey Infrared
Fluorescence Imaging System (LI-COR) and protein levels
were determined as integrated intensities of fluorescence
and analyzed using the Odyssey software (LI-COR Inc.).
Statistical analysis
Statistical comparisons were performed using Origin soft-
ware (Microcal Software, Northampton, MA). Compari-
sons between mean values were performed using the
Student paired t test. P value <0.05 was considered signif-
icant.
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